Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration

Br J Ophthalmol. 2008 Jan;92(1):74-5. doi: 10.1136/bjo.2007.128942.

Abstract

Aims: This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium (Macugen) and Photodynamic Therapy (PDT) in predominantly classic juxtafoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) in seven eyes of seven patients.

Results: Best corrected visual acuity (BCVA) diminished with a mean of five letters. Initial area of CNV increased significantly from 1.4 mm2 to 2.7 mm2. There was a significant increase in the greatest linear dimension (GLD) from 1280.3 microm to 2065.7 microm at the 24-week follow-up.

Conclusion: Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Aptamers, Nucleotide / therapeutic use*
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Combined Modality Therapy
  • Female
  • Humans
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy*
  • Male
  • Middle Aged
  • Photochemotherapy*
  • Prospective Studies
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / drug effects

Substances

  • Angiogenesis Inhibitors
  • Aptamers, Nucleotide
  • Vascular Endothelial Growth Factor A
  • pegaptanib